This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $217.90 to $238.70 in the past one-month time frame.The upmove came after an appeals court ruled in favor of the company, upholding the validity of two patents on its rheumatoid arthritis drug Enbrel.